Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
2018 First Quarter results presentation
Operating income, growth figures, profitability and how our products have behaved.
Wed, 25/04/2018 - 12:15
0 min
Download related document
Select rating
Give 2018 First Quarter results presentation 1/5
Give 2018 First Quarter results presentation 2/5
Give 2018 First Quarter results presentation 3/5
Give 2018 First Quarter results presentation 4/5
Give 2018 First Quarter results presentation 5/5
No votes yet
Related
First nine months 2024 results press release
Operating revenue in the first nine months of 2024 was 564.6 million euros, a 5% decrease on the first nine months of 2023, mainly due...
4 min
07/11/2024
ROVI completes the strategic review of its CDMO business
Madrid, Spain - 24 October 2024 – Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical company that...
2 min
24/10/2024
First half 2024 results press release
ROVI ACHIEVED OPERATING REVENUE OF 329.3 MILLION EUROS AND INCREASED ITS GROSS MARGIN BY 2.8 PERCENTAGE POINTS Operating revenue in...
7 min
31/07/2024
See More
Email
Facebook
Twitter
LinkedIn